Ink dries on Hologic's deal to buy Mobidiag

By staff writers

June 17, 2021 -- Hologic announced the completion of its $808 million acquisition of biotechnology company Mobidiag. The Finnish-French company develops near-patient, acute-care molecular diagnostic testing products.

Mobidiag's product line includes molecular diagnostic instruments and tests for acute care conditions, including gastrointestinal and respiratory infections, antimicrobial resistance management, and healthcare-associated infections, according to a release.

The acquisition was first announced in April this year.

Hologic's growth continues in Q2
Hologic has continued to post significant increases in revenue, with revenues doubling in the company's second quarter. The growth was driven primarily...
Hologic acquires Diagenode for $159 million
Hologic has purchased European molecular diagnostic assay and epigenetic product developer Diagenode for $159 million in a deal that will expand...
Market for COVID-19 diagnostics to hit $38B by year end
As the unfortunate milestone of one full year of the global COVID-19 pandemic worldwide is reached, the diagnostic industry has been changed, perhaps...
Hologic wraps up Biotheranostics acquisition
Hologic has completed the acquisition of cancer test developer Biotheranostics. Hologic is gaining access to two laboratory-developed tests as part of...
Hologic inks deal with Google to unite cloud with diagnostics
Hologic has announced a collaboration with Google designed to advance the potential of digital diagnostics for cervical cancer screening by making Google...

Copyright © 2021

Last Updated ls 6/17/2021 2:46:01 PM